Category Archives: biotechnology

Omeros (OMER) Stock Rallies 149% on $2 Billion Novo Nordisk Deal

Omeros Corporation (NASDAQ: OMER) stock soared 149% to close at $10.19 on October 15, up $6.09 from the previous day’s close of $4.10. This dramatic surge followed the announcement of a $2.1 billion licensing and asset purchase agreement with Danish pharmaceutical giant Novo Nordisk for Omeros’ MASP-3 inhibitor drug candidate, zaltenibart (formerly OMS906).

### Significant Licensing Deal with Novo Nordisk

The deal grants Novo Nordisk exclusive worldwide rights to develop and commercialize zaltenibart, which targets rare blood and kidney disorders. Under the agreement, Omeros will receive $340 million in upfront and near-term payments, with potential milestone payments boosting the total deal value to $2.1 billion. Additionally, Omeros stands to earn royalties on future sales if zaltenibart successfully reaches the market.

Trading volume exploded to 77.9 million shares on October 15, a huge increase compared to the typical daily volume of 1.2 million shares. The stock opened the day at $11.53, hitting an intraday high of $12.77 before settling at $10.19. Over the past 52 weeks, OMER stock has traded between $0.92 and $12.87.

### Financial Position and Impact of the Deal

As of June 30, 2025, Omeros held just $28.7 million in cash and short-term investments and reported a cash burn of $58.9 million during the first half of the year. Without any current product sales and operating at a chronic loss, the company’s financial position has been precarious.

The $340 million upfront payment from Novo Nordisk is expected to bolster Omeros’ cash reserves significantly, enabling the company to pay down debts and fund operations for more than a year. Despite this, at midday on October 15, Omeros’ market capitalization was just under $700 million.

### Update on Lead Drug Candidate: Narsoplimab

While zaltenibart is a promising asset, it is not Omeros’ most advanced drug candidate. Their lead product, narsoplimab, a MASP-2 inhibitor, is currently under FDA review for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The FDA initially rejected narsoplimab’s application in 2021, citing difficulties in estimating treatment effects and requesting additional data.

Omeros submitted further data in December 2021. The FDA set an initial target decision date of September 25, 2025, but this was later extended to December 26, 2025. This delay extends the uncertainty regarding narsoplimab’s approval and commercial potential.

Adding to the concerns, narsoplimab failed a pivotal 2023 trial testing its efficacy in treating kidney damage from an autoimmune disorder different from HSCT-TMA. Moreover, the FDA likely requested a randomized controlled trial in 2021, a study Omeros did not conduct. Instead, the company compared a small group of 28 treated patients to similar untreated patients outside the trial.

### Looking Ahead

Omeros signaled in August 2025 that a significant deal was imminent, highlighting advanced negotiations around zaltenibart. The licensing agreement with Novo Nordisk represents a critical milestone for Omeros, potentially stabilizing the company’s finances while expanding the development prospects of zaltenibart under a major pharmaceutical partner.

Investors will be closely watching the FDA’s December decision on narsoplimab, which remains pivotal to Omeros’ future commercial success.

*The above content is based on developments as of October 15, 2025.*
https://bitcoinethereumnews.com/tech/omeros-omer-stock-rallies-149-on-2-billion-novo-nordisk-deal/?utm_source=rss&utm_medium=rss&utm_campaign=omeros-omer-stock-rallies-149-on-2-billion-novo-nordisk-deal

Dyne’s Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data

Dyne Therapeutics Inc. (NASDAQ: DYN) stands out as one of the best stocks to buy under $20.

On September 29, Dyne Therapeutics announced a significant milestone: Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation for its investigational therapeutic, DYNE-251.

This designation targets individuals with Duchenne muscular dystrophy (DMD) who have mutations in the DMD gene that are amenable to treatment with DYNE-251.

The Orphan Drug status is a crucial step in the development of DYNE-251, potentially providing benefits such as market exclusivity and regulatory assistance, which can accelerate the availability of this promising therapy for patients in need.

Investors and stakeholders will be closely watching Dyne Therapeutics as it advances its pipeline and seeks to address unmet medical needs in the muscular dystrophy community.
https://ca.finance.yahoo.com/news/dyne-investigational-dmd-drug-dyne-205457972.html

Researcher develops method for protein-protein structure prediction

A Nigerian researcher, Muinat Zubair, has developed an innovative method for predicting protein structure and protein-protein interactions by combining experimental and computational approaches.

Zubair made this discovery during her time as a graduate teaching and research assistant at Tennessee Technological University, USA, where she earned her MSc in chemistry. Speaking about her work, she explained that her research contributes to solving the protein folding problem—a challenge that has perplexed scientists for over 50 years.

“I used artificial intelligence software to predict the full-length structures and interaction between two mammalian enzymes,” Zubair said. These proteins are part of the larger mitogen-activated protein kinase (MAPK) pathway, which is activated in response to cellular stress. According to her, malfunction in this pathway worsens symptoms of several neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).

“Understanding the structures of these proteins and how they bind and activate each other will help us develop therapeutic targets to manage these diseases and improve outcomes for patients and their families,” she added.

Neurodegenerative diseases are increasingly becoming a global pandemic, affecting millions of people worldwide. Zubair highlighted that this number is expected to rise as the global population of older adults grows.

The steady-state kinetics of these proteins had never been studied prior to her research. Supervised by Dr. Xuanzhi Zhan, she determined their apparent Michaelis-Menten parameters through kinase assays and Western blot quantification.

In addition, Zubair predicted the full-length structures and protein-protein interactions using AlphaFold2 and AlphaFold-Multimer—two cutting-edge artificial intelligence tools designed to elucidate the structure and behavior of proteins and other macromolecules.

“Previously, X-ray diffraction studies had only solved the structures of the kinase domains of these proteins,” she explained. “However, prior research showed that other parts of the enzymes also contribute to binding and activation, emphasizing the need to predict the entire structure.”

To validate her findings, Zubair used additional computational methods. “I applied molecular dynamics simulations to test and confirm protein stability and performed protein frustratometer analysis, contact mapping, and other assessments on the interface between the docked proteins. The protein structures remained stable under simulated physiological conditions,” she noted.

Beyond pioneering kinetic data on the MAPK pathway, Zubair emphasized that the computational methods she employed could be applied broadly to study other proteins. Nevertheless, she acknowledges that computational results require validation through wet-laboratory experiments.

“That is the next stage of the project,” she said. “It involves site-directed mutagenesis and studying the other two isoforms of the enzyme to further validate our results.”

Originally from Iganna in Oyo State, Nigeria, Zubair grew up in Ibadan and earned her first degree in biochemistry from Ladoke Akintola University of Technology (LAUTECH), Nigeria. She is currently pursuing a doctoral degree in the highly selective Purdue University Interdisciplinary Life Science program (PULSe) and was awarded the prestigious Lynn Fellowship to support her PhD studies.

Looking ahead, Zubair expresses a strong commitment to advancing human health, particularly in the field of neurodegenerative diseases. “I find so much fulfillment knowing that I could potentially discover a druggable target or help improve our understanding of these diseases,” she said.
https://tribuneonlineng.com/researcher-develops-method-for-protein-protein-structure-prediction/